113 related articles for article (PubMed ID: 19922546)
1. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
[TBL] [Abstract][Full Text] [Related]
2. Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015.
Kinlaw AC; Jonsson Funk M; Conover MM; Pate V; Markland AD; Wu JM
Med Care; 2018 Feb; 56(2):162-170. PubMed ID: 29287033
[TBL] [Abstract][Full Text] [Related]
3. What is the best first choice oral drug therapy for OAB?
Sahai A; Robinson D; Abrams P; Wein A; Malde S
Neurourol Urodyn; 2024 Jan; ():. PubMed ID: 38270332
[TBL] [Abstract][Full Text] [Related]
4. The Use of Metformin in Overactive Bladder: A Retrospective Nested Case-control, Population-based Analysis.
Neu S; Matta R; Locke JA; Troke N; Tadrous M; Saskin R; Rebullar K; Nam R; Herschorn S
Urology; 2024 Jan; 183():70-77. PubMed ID: 37805050
[TBL] [Abstract][Full Text] [Related]
5. Is behavioral therapy plus antimuscarinic better than drug alone to treat overactive bladder?
Chancellor MB; Hasenau DL
Rev Urol; 2008; 10(4):306-8. PubMed ID: 19145277
[No Abstract] [Full Text] [Related]
6. The concern about noradrenergic and antimuscarinic agents for OSA.
Wang D; Chen R; Zhang N
Sleep Biol Rhythms; 2022 Apr; 20(2):319-320. PubMed ID: 38469266
[No Abstract] [Full Text] [Related]
7. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting.
Asche CV; Kim J; Kulkarni AS; Chakravarti P; Andersson KE
BJU Int; 2012 Feb; 109(4):572-80. PubMed ID: 21777361
[TBL] [Abstract][Full Text] [Related]
8. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review.
İlhan B; Erdoğan T; Topinková E; Bahat G;
Eur Geriatr Med; 2023 Aug; 14(4):733-746. PubMed ID: 37245173
[TBL] [Abstract][Full Text] [Related]
9. Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions.
Rutman MP; Horn JR; Newman DK; Stefanacci RG
Clin Drug Investig; 2021 Apr; 41(4):293-302. PubMed ID: 33713027
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study.
Katoh T; Kakizaki H; Lee KS; Ishida K; Katou D; Yamamoto O; Jong JJ; Sumarsono B; Uno S; Yamaguchi O
Low Urin Tract Symptoms; 2021 Jan; 13(1):98-107. PubMed ID: 32975024
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
Herschorn S; Staskin D; Schermer CR; Kristy RM; Wagg A
Drugs Aging; 2020 Sep; 37(9):665-676. PubMed ID: 32725584
[TBL] [Abstract][Full Text] [Related]
12. A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.
Wróbel A; Szopa A; Serefko A; Poleszak E
Molecules; 2020 Mar; 25(6):. PubMed ID: 32197469
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Potentially Inappropriate Bladder Antimuscarinic Use in People with Dementia: A Retrospective Cohort Study.
Green AR; Segal J; Boyd CM; Huang J; Roth DL
Drugs Real World Outcomes; 2020 Jun; 7(2):151-159. PubMed ID: 32052322
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Katoh T; Igawa Y; Yamaguchi O; Kato D; Hamada T; Kuroishi K
Low Urin Tract Symptoms; 2020 Jan; 12(1):68-80. PubMed ID: 31571403
[TBL] [Abstract][Full Text] [Related]
15. Re: Letter to editor: heart rate effects of antimuscarinic drugs.
Cetinel B; Onal B; Gultekin MH
Int Urol Nephrol; 2019 Oct; 51(10):1785-1786. PubMed ID: 31352582
[No Abstract] [Full Text] [Related]
16. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
17. Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia?
Miotla P; Olejniczak P; Futyma K; Wrobel A; Tomaszewski M; Bogusiewicz M; Wawrysiuk S; Markut-Miotla E; Rechberger T
J Clin Med; 2018 Sep; 7(9):. PubMed ID: 30205603
[TBL] [Abstract][Full Text] [Related]
18. Overactive Bladder is a Distress Symptom in Heart Failure.
Son YJ; Kwon BE
Int Neurourol J; 2018 Jun; 22(2):77-82. PubMed ID: 29991228
[TBL] [Abstract][Full Text] [Related]
19. Mirabegron: A Review in Overactive Bladder Syndrome.
Deeks ED
Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
